Financial intelligence for Asia's healthcare markets
Remember me:

New Zealand: Arvida to buy three villages for NZ$106 million

Retirement village operator Arvida is to acquire three villages – Mary Doyle Lifecare, Strathallan Lifecare and 50% of Village at the Park Lifecare – from Hurst Lifecare for approximately NZ$106 million (US$76.7 million).

“Meaningful brownfield development at Village at the Park and Mary Doyle includes 110 consented new units in the pipeline” said Bill McDonald, CEO of Arvida. “The new units will be progressively developed over the next four years and include developments nearing completion”.

The acquisitions will increase the number of Arvida villages to 29 comprising a mix of 1,761 care beds and 1,752 retirement units. And based on Arvida’s estimates of earnings, the acquisitions will add NZ$9 million of underlying profit on a pro forma FY18 basis and be 8% accretive to underlying earnings per share.

The acquisitions and transaction costs are to be funded through a combination of new equity and debt. The majority, or NZ$77 million of new equity is to be raised by way a 1-for-5 pro-rata renounceable rights issue at NZ$1.15 per share. The offer has been fully underwritten by Forsyth Barr. Of the remainder, NZ$16 million shares will be issued to vendors (escrowed for twelve months); and the remaining NZ$16 million from bank debt. Arvida said that this left headroom for further acquisitions and brownfield development.

Completion is expected mid October.

Posted on: 13/09/2017 UTC+08:00


News

Beijing-based healthcare service platform Miaoshou Doctor has completed a ¥1.5 billion (US$232 million) Series F round of financing.
Chinese digital technology company, Xisoft Technology, which focuses on hospital operation management, has raised ¥100 million ($15.65 million) in Series A+ financing.
Hearing health company Olive Union has closed a $7M Series B round led by Beyond Next Ventures, Bonds Investment Groups and Japan Policy Finance Corporation.
Long Hill Capital, a venture capital firm in China, has closed on more than $300 million for its third fund on 15 March.
Eluminex Biosciences, an ophthalmic biotechnology company has completed a $50 million Series A financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital.
TVM Capital Healthcare, a global private equity and growth capital firm focused on emerging markets, has announced two team additions today.
In partnership with VeChain and DNV GL, Renji Hospital, a hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has launched the world's first blockchain-enabled intelligent tumour treatment centre.
Hong Kong-based BuyHive, a new global sourcing start-up that connects buyers with trusted verified overseas suppliers, has launched a PPE programme to help US companies optimise their post-Covid supply chains.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed










A Rolex Yacht-Master I Ladies Replica watch is basically a person watch that's crafted inside an identical fashion with a well-known maker¡¯s real piece. Purchasing Replica Watches seems as an excellent idea. Anyway,ON perfectcloneshop.com replica Rolex Yacht-Master Ladies watches are affordable, look almost the identical while using real ones and could easily acquired.